Document ID: 32022C0316(02)
Language: ENG

<table><col/><col/><col/><col/><tbody><tr><td><p>16.3.2022&#160;&#160;&#160;</p></td><td><p>EN</p></td><td><p>Official Journal of the European Union</p></td><td><p>C 121/2</p></td></tr></tbody></table>
Statement of the Commission on Directive (EU) 2022/431 of the European Parliament and of the Council amending Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens or mutagens at work ( 1 )
Hazardous medicinal products
(2022/C 121/02)
The Commission highlights the importance of protecting workers from the adverse health effects that occupational exposure to certain hazardous medicinal products can have.
In this regard, it is acknowledged that certain hazardous medicinal products which contain one or several substances meeting the criteria for classification as carcinogenic (categories 1A or 1B), mutagenic (categories 1A or 1B) or reprotoxicant (categories 1A or 1B) in accordance with Regulation (EC) No 1272/2008 fall under the scope of Directive 2004/37/EC.
<note>
( 1 ) OJ L 88, 16.3.2022, p. 1 .
</note>